Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD

104.56

-0.50

(-0.48%)

At close: 04:00PM EST

104.43

-0.13

(-0.12%)

After hours:

07:55PM EST

Loading interactive chart...

Yahoo Finance
Allurion launches compounded GLP-1 program as FDA aims to end access
Allurion joins the pack to offer compounded GLP-1 access for patients.
Premium
MT Newswires
Drug Compounders Fight Drugmaker Efforts to Push Them Out of Market for GLP-1 Medications
An industry trade group representing drug-compounding companies is asking US regulators to continue categorizing Novo Nordisk's Wegovy, Ozempic, and other GLP-1 agonist medications as "currently in shortage," which would allow them to keep filling prescriptions for the popular weight-loss drugs' using their active ingredients.